Ascentage Pharma Group International (AAPG) had its "buy" rating reaffirmed by BTIG Research. They now have a $48.00 price target on the stock.
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
Ascentage Pharma Group International (AAPG) was upgraded by BTIG Research to "strong-buy".
Ascentage Pharma Group International (AAPG) had its "buy" rating reaffirmed by BTIG Research. They now have a $48.00 price target on the stock.